Livita

Livita is a combination nutritional/hematinic preparation used for the treatment and prevention of combined iron, vitamin B-complex, and zinc deficiency. Its main uses, classified by strength of evidence, are:

Established / guideline-supported uses

• Treatment of mild-to-moderate iron-deficiency anemia when accompanied by vitamin B-complex and/or zinc insufficiency, where a combined preparation is clinically appropriate.
• Prevention and treatment of nutritional deficiency of iron, B-complex vitamins, and zinc during pregnancy and lactation, when increased requirements are not met by diet alone.
• Nutritional supplementation in children and adults with dietary insufficiency, poor intake, or increased physiological demand (growth, convalescence after illness).

Adjunct / supportive use

• As an adjunct to dietary correction and treatment of the underlying cause of deficiency (e.g., blood loss, malabsorption), not as a substitute for identifying and managing that cause.

Note: Livita is a fixed combination and is not the preferred choice when an isolated, severe single-nutrient deficiency (for example severe iron-deficiency anemia alone) requires higher-dose single-agent therapy; in such cases a physician may prefer a single-ingredient iron product instead.

Formulations of Livita marketed in Bangladesh typically contain, per dose unit (strength varies by brand and dosage form - syrup, capsule, or drops):

• Elemental iron 50 mg (as Iron (III)-hydroxide polymaltose complex) per 5 mL, or equivalent per capsule
• Thiamine hydrochloride (Vitamin B1) - approx. 5 mg
• Riboflavin sodium phosphate (Vitamin B2) - approx. 2 mg
• Pyridoxine hydrochloride (Vitamin B6) - approx. 2 mg
• Nicotinamide (Vitamin B3) - approx. 20 mg
• Elemental zinc (as zinc sulphate monohydrate) - approx. 10 mg

Exact strengths differ between brands; always check the product label/pack insert for the specific formulation dispensed.

Livita is a multi-ingredient oral supplement combining a non-ionic, polymaltose-bound form of trivalent (ferric) iron with B-complex vitamins (thiamine, riboflavin, pyridoxine, nicotinamide) and elemental zinc. The iron in this product is bound in a stable macromolecular complex rather than existing as a simple ionic (ferrous) salt, which is associated with more controlled intestinal absorption and generally better gastrointestinal tolerability than conventional ferrous iron salts (e.g., ferrous sulfate).

Livita is used to correct or prevent combined deficiency of iron, B-complex vitamins, and zinc, which commonly occurs together in pregnancy, lactation, childhood growth, and states of poor dietary intake or increased nutritional demand.

Livita belongs to the therapeutic class of Iron and Vitamin Combined Preparations (hematinics with multivitamin/mineral supplementation), used as a nutritional supplement and antianemic agent.

Livita combines three pharmacologically distinct components:

• Iron (III)-hydroxide polymaltose complex: Unlike ionic ferrous salts, this non-ionic complex is absorbed through a controlled, active (carrier-mediated) mechanism at the mucosal surface of the duodenum and proximal jejunum, rather than by passive diffusion. This limits the amount of unbound free iron reaching the bloodstream, which is thought to reduce the pro-oxidant gastrointestinal irritation seen with ferrous salts. Absorbed iron is transported bound to transferrin, stored as ferritin in the liver, spleen and bone marrow, and incorporated into hemoglobin, myoglobin, and iron-containing enzymes.
• B-complex vitamins (thiamine, riboflavin, pyridoxine, nicotinamide): Function as coenzymes/coenzyme precursors in carbohydrate, fat, and protein metabolism, and support normal red blood cell formation and nervous system function.
• Zinc: An essential trace element that is a cofactor for numerous enzymes and is required for normal growth, immune function, wound healing, and taste/appetite regulation.

Livita is taken orally. It may be taken with or after meals to improve gastrointestinal tolerability; unlike conventional ferrous iron salts, iron polymaltose complex absorption is less significantly reduced by food, so it can be given with meals if GI upset occurs on an empty stomach. Shake liquid formulations well before use and measure the dose with the measuring cup/spoon provided. Do not mix directly with tea, coffee, milk, or calcium-rich foods/supplements at the same time, as these may still reduce absorption; separate intake from these by at least 1-2 hours where possible.

Because iron in Livita is bound in a stable polymaltose complex rather than existing as a free ionic salt, it is less prone to the classic chelation-type interactions seen with ferrous iron salts, but some clinically relevant interactions still apply:

• Tetracycline and fluoroquinolone antibiotics: Concurrent iron and zinc intake can reduce absorption of these antibiotics (and vice versa) through chelate formation; separate dosing by at least 2-3 hours.
• Other oral iron or mineral supplements: Concomitant use with other iron-containing products should be avoided to prevent cumulative iron overload.
• Penicillamine and levodopa: Zinc and iron may reduce absorption/efficacy of these drugs; separate administration times if co-prescribed.
• Antacids and calcium/phytate/tannin-rich foods (tea, coffee): May modestly reduce absorption of the iron and zinc components; the polymaltose-bound iron is less affected than ferrous salts, but spacing intake from these substances is still advisable.

Livita is generally well tolerated, with gastrointestinal side effects that are typically milder than those seen with conventional ferrous iron salts. Reported side effects include:

• Nausea, epigastric discomfort or fullness
• Constipation or, less commonly, diarrhea
• Dark or discolored stools - this is an expected, harmless effect of the iron component and does not indicate gastrointestinal bleeding
• Mild vomiting or dyspepsia in some patients
• Uncommonly, metallic taste or mild headache

Most gastrointestinal effects are dose-related and can often be reduced by taking the dose with food.

Livita is commonly used to meet the increased nutritional demand for iron, B-vitamins, and zinc during pregnancy and lactation, and combination iron/multivitamin/mineral supplements of this type are frequently recommended in this setting. However, as with any supplement taken during pregnancy or breastfeeding, it should be used only under medical supervision, at the dose advised by the physician, with the potential benefit weighed against any individual risk factors. Excessive supplementation beyond the prescribed dose should be avoided. Consult a physician before use if pregnant, planning pregnancy, or breastfeeding.

The following precautions apply to the use of Livita :

• Iron overload risk: Use with caution in patients with a history of, or risk factors for, iron overload; monitor iron status during prolonged use (see Contraindications for absolute iron-overload contraindications).
• Accidental ingestion by children: Although iron polymaltose complex has a different, generally less acutely toxic profile than ferrous iron salts in accidental overdose, all iron-containing products should still be kept out of reach of children, as unsupervised ingestion of a large quantity can still be harmful.
• Zinc component - chronic excess intake: Prolonged use of doses higher than recommended can lead to zinc-induced copper deficiency, which may cause anemia and neurological effects; do not exceed the prescribed dose or duration without medical advice.
• Absorption-reducing substances: Tea, coffee, and calcium-rich foods or supplements may reduce absorption of the iron and zinc components if taken at the same time; space intake apart where practical.
• Gastrointestinal disease: Use with caution in patients with active peptic ulcer disease, ulcerative colitis, or other significant GI disorders, as gastrointestinal symptoms may be aggravated.

Deliberate or accidental overdose of Livita should be treated as a medical emergency. While the iron polymaltose complex in this product has a different and generally less acutely dangerous overdose profile than conventional ferrous iron salts (due to its controlled, non-passive absorption), taking a much larger than recommended amount can still cause epigastric pain, nausea, vomiting, diarrhea, and, in significant overdose, metabolic acidosis or other systemic effects.

If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to treat an overdose at home; take the product container with you to the hospital. Do not induce vomiting unless specifically instructed by a medical professional or poison control.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use: Livita is used in children, including infants, for treatment/prevention of combined iron, B-complex, and zinc deficiency, using age- and weight-based dosing under medical supervision (see Pediatric Uses).

Elderly: No specific dose reduction is typically required in the elderly, but iron status and renal/GI function should be considered; use the lowest effective dose.

Renal impairment: Specific dose-adjustment data for this fixed combination in renal impairment are limited; use with caution and physician supervision.

Hepatic impairment: Use with caution, as iron metabolism/storage can be affected in significant liver disease; specific dose-adjustment data are limited for this combination.

Pregnancy and lactation: See Pregnancy and Lactation section above.

Duration of treatment with Livita depends on the indication and the degree of deficiency, and should be determined by the prescribing physician. For correction of iron-deficiency anemia, treatment is typically continued for several weeks after hemoglobin returns to normal (commonly an additional 4-12 weeks) in order to replenish body iron stores. For general nutritional supplementation (e.g., during pregnancy/lactation), it may be continued for the relevant period as advised by the physician. Response should be monitored periodically (e.g., hemoglobin/iron studies) and treatment duration adjusted accordingly.

Hematinics; Iron and vitamin combined preparations; Multivitamin and mineral (nutritional) supplements

The iron component of Livita - iron (III)-hydroxide polymaltose complex - is absorbed via a controlled, receptor/carrier-mediated active transport mechanism at the intestinal mucosa (mainly duodenum and proximal jejunum), in contrast to the passive diffusion of ionic iron from ferrous salts. This limits free unbound iron in the circulation and is associated with better gastrointestinal tolerability. Absorbed iron binds to transferrin for transport, is stored as ferritin, and is incorporated into hemoglobin and iron-dependent enzymes. The accompanying B-complex vitamins act as essential coenzymes in energy and hematopoietic metabolism, while zinc serves as a cofactor for enzymes involved in growth, immune function, and cellular metabolism.

Livita is used in pediatric patients, including infants and older children, for the prevention and treatment of combined iron, vitamin B-complex, and zinc deficiency, using age- and weight-appropriate liquid (syrup/drops) formulations. Typical guidance:

• Infants: weight-based dosing (approximately 0.3 mL/kg/day of syrup, divided), only under physician guidance.
• Older children: approximately 5 mL syrup, one to three times daily, adjusted to age and severity of deficiency.

As with all iron-containing products, caution parents/caregivers about safe storage out of reach of children, since accidental ingestion of a large quantity can be harmful even though this iron form is generally less acutely toxic than ferrous iron salts. Safety and efficacy in neonates and very young infants should be established by a pediatrician on a case-by-case basis.